Waugh John, Keating Gillian M, Plosker Greg L, Easthope Stephanie, Robinson Dean M
Adis International Limited, Auckland, New Zealand.
Drugs. 2006;66(1):85-109. doi: 10.2165/00003495-200666010-00005.
Pioglitazone is an antihyperglycaemic agent that, in the presence of insulin resistance, increases hepatic and peripheral insulin sensitivity, thereby inhibiting hepatic gluconeogenesis and increasing peripheral and splanchnic glucose uptake. Pioglitazone is generally well tolerated, weight gain and oedema are the most common emergent adverse events, and there are no known drug interactions between pioglitazone and other drugs. In clinical trials in patients with type 2 diabetes mellitus, pioglitazone as monotherapy, or in combination with metformin, repaglinide, insulin or a sulphonylurea, induced both long- and short-term improvements in glycaemic control and serum lipid profiles. Pioglitazone was also effective in reducing some measures of cardiovascular risk and arteriosclerosis. Pioglitazone thus offers an effective treatment option for the management of patients with type 2 diabetes.
吡格列酮是一种抗高血糖药物，在存在胰岛素抵抗的情况下，可增加肝脏和外周胰岛素敏感性，从而抑制肝脏糖异生并增加外周和内脏葡萄糖摄取。吡格列酮一般耐受性良好，体重增加和水肿是最常见的突发不良事件，且尚无已知的吡格列酮与其他药物之间的药物相互作用。在2型糖尿病患者的临床试验中，吡格列酮单药治疗或与二甲双胍、瑞格列奈、胰岛素或磺脲类药物联合使用，均可在长期和短期内改善血糖控制及血脂谱。吡格列酮在降低某些心血管风险和动脉硬化指标方面也有效。因此，吡格列酮为2型糖尿病患者的管理提供了一种有效的治疗选择。
